Clinical trials: Blood Transfusion
Arthroplasty, Replacement, Knee, Blood Transfusion, Autologous
A Clinical Study to Investigate if Transfusion of Patients Own Shed Blood Improves the Immunological Status in Comparison to Transfusion of Donor Blood ("Bank Blood")
The primary objective of the study is to compare the immunological status after either autologous blood transfusion as administered by Bellovac® ABT or allogenic blood transfusion, with regards to change in Natural Killer (NK)…
- Conditions
- Arthroplasty, Replacement, Knee, Blood Transfusion, Autologous, Blood Transfusion
- Trial name
- NCT00839241
- Testing
- Bellovac ABT, Allogenic Blood Transfusion
- Where
- Poland
- Volunteers
- 45 people
- Sponsor
- Wellspect HealthCare
Myelodysplastic Syndromes, Anemia
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
The purpose of this study is to demonstrate that Epoetin alfa treatment reduces red blood cell transfusions in anemic patients with myelodysplastic syndromes (MDS).
- Trial name
- NCT00695396
- Testing
- Epoetin alfa
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
This trial is conducted in Canada, Asia, Europe and USA. The aim of this clinical trial is to investigate the effect and safety of rFXIII on transfusion needs in patients undergoing heart surgery.
- Trial name
- NCT00914589
- Testing
- catridecacog
- Where
- 32 sites in United States, Canada and 8 more
- Volunteers
- 479 people
- Sponsor
- Novo Nordisk A/S
Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
Study to evaluate patient preference of deferasirox film-coated tablet (FCT) or deferasirox dispersible tablet (DT) in patient with transfusion - dependent thalassemia or non-transfusion -dependent thalassemia as measured by…
- Trial name
- Jupiter (NCT02993224)
- Testing
- Deferasirox dispersable tablet (DT), Deferasirox film coated tablet (FCT)
- Where
- 17 sites in Egypt, Lebanon and 5 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndrome (MDS)
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).
- Trial name
- NCT01459159
- Testing
- ezatiostat hydrochloride (Telintra®)
- Where
- 7 sites in United States
- Volunteers
- 162 people
- Sponsor
- Telik
Surgery
Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management
This is a multi-center cluster-randomized trial with the following Specific Aims: To evaluate if continuous noninvasive hemoglobin monitoring will reduce the RBC transfusions in patients undergoing surgeries associated with a…
- Trial name
- NACHO (NCT01686659)
- Testing
- Continuous Noninvasive Hemoglobin Monitoring
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 470 people
- Sponsor
- Society for the Advancement of Blood Management, Inc
Myelodysplastic Syndromes
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
The study will enroll low risk MDS patients who need red blood cell transfusions and who are refractory to or are not using erythropoiesis-stimulating agents.
- Trial name
- NCT01904682
- Testing
- Oral rigosertib
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 45 people
- Sponsor
- Traws Pharma, Inc.
Myelodysplastic Syndrome
APG101 in Myelodysplastic Syndrome
It has been shown in preclinical experiments with bone marrow from patients with myelodysplastic syndrome that APG101 rescues erythrocytes from premature cell death.
- Trial name
- APG101 in MDS (NCT01736436)
- Testing
- Treatment with APG101, Bone marrow collection, Blood drawings
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Apogenix GmbH
Beta Thalassemia Intermedia
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)
The purpose was to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of sapablursen administered subcutaneously to participants with non-transfusion dependent β-Thalassemia Intermedia.
- Trial name
- NCT04059406
- Testing
- sapablursen
- Where
- 19 sites in Australia, Greece and 3 more
- Volunteers
- 29 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Beta Thalassemia Transfusion Dependent
Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec
This study will assess the safety and efficacy of deferasirox in patients with cardiac MRI T2* < 20 msec.
- Trial name
- NCT00879242
- Testing
- Deferasirox
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndrome
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Evaluation of the Efficacy and Safety of Oral Azacitidine plus Best Supportive care versus Placebo and Best Supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to…
- Trial name
- NCT01566695
- Testing
- Oral Azacitidine, Best Supportiv Care (BSC)
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 216 people
- Sponsor
- Celgene
Myelodysplastic Syndrome, Anemia
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
The main aim of this study is to assess how much elritercept reduces the need for RBC (red blood cell) transfusions and improves hemoglobin blood values in addition to how safe elritercept is when compared with epoetin alfa.
- Trial name
- ELRiSE MDS (NCT07422480)
- Testing
- Elritercept, Epoetin Alfa
- Where
- 162 sites in United States, Argentina and 26 more
- Volunteers
- 300 people
- Sponsor
- Takeda
Beta-Thalassemia
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
This is a non-randomized, open label, multi-site, single-dose, phase 1/2 study in subjects with Transfusion-Dependent β-Thalassemia (TDT).
- Trial name
- NCT05577312
- Testing
- BRL-101
- Where
- 7 sites in China
- Volunteers
- 39 people
- Sponsor
- Bioray Laboratories
Primary Myelofibrosis, MPN-associated Myelofibrosis
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global…
- Trial name
- RESUME (NCT01178281)
- Testing
- Pomalidomide 0.5 mg, Pomalidomide
- Where
- 87 sites in United States, Australia and 14 more
- Volunteers
- 267 people
- Sponsor
- Celgene
Aplastic Anemia
A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment
This research study is testing a medicine called avatrombopag in adults with aplastic anemia, a rare condition where the bone marrow does not produce enough blood cells.
- Trial name
- NCT07786922
- Testing
- Avatrombopag 20 mg Oral Tablet
- Volunteers
- 26 people
- Sponsor
- Swedish Orphan Biovitrum
Aplastic Anemia
CK0801 for Treatment of Aplastic Anemia
This Phase 2, multicenter, open-label study is evaluating CK0801 for the treatment of aplastic anemia in adults with persistent transfusion dependence after at least one prior line of therapy or intolerance to standard-of-care…
- Trial name
- NCT07499102
- Testing
- CK0801
- Volunteers
- 12 people
- Sponsor
- Cellenkos, Inc.
Spinal Surgery
Comparison Between Return and Wastage of Your Own Blood, Collected During Spinal Surgery, for Verification of Safety When Returning Blood
The study is an open, randomized, controlled, single-centre study including a total of 42 evaluable subjects scheduled for spinal surgery with an approximate expected bleeding of 800-1500 ml.
- Trial name
- NCT01251042
- Testing
- Sangvia
- Where
- Denmark
- Volunteers
- 51 people
- Sponsor
- Wellspect HealthCare
Iron Overload Due to Repeated Red Blood Cell Transfusions
Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy
The purpose of this study is to evaluate SSP-004184AQ in patients with transfusional iron overload whose primary diagnosis is hereditary or congenital anemia.
- Trial name
- NCT01604941
- Testing
- SPD602
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 32 people
- Sponsor
- Shire
Glioblastoma Multiforme
Dendritic Cell Cancer Vaccine for High-grade Glioma
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and…
- Trial name
- GBM-Vax (NCT01213407)
- Testing
- Trivax, Temozolomide, Surgery, Radiotherapy, Temozolomide, Surgery, Radiotherapy
- Where
- 8 sites in Austria
- Volunteers
- 87 people
- Sponsor
- Activartis Biotech
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome
Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
The primary purpose of this study is to determine the safety and tolerability of SLN124 for the treatment of non-transfusion-dependent (NTD) β-thalassaemia and low risk myelodysplastic syndrome.
- Trial name
- NCT04176653
- Where
- 5 sites in Bulgaria, United Kingdom
- Sponsor
- Silence Therapeutics plc